Eton Pharmaceuticals Q4 2023 GAAP EPS $(0.09) Misses $(0.04) Estimate, Sales $7.313M Miss $7.700M Estimate
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals (NASDAQ:ETON) reported Q4 2023 earnings with a GAAP EPS of $(0.09), missing the $(0.04) estimate, and sales of $7.313M, missing the $7.700M estimate. This represents a 13.94% decrease in sales compared to the same period last year.
March 14, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eton Pharmaceuticals reported lower than expected Q4 2023 earnings and sales, missing both EPS and revenue estimates.
Missing both EPS and revenue estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. The significant miss in EPS by 125% and the miss in sales estimates, along with a 13.94% decrease in sales compared to the previous year, are likely to be viewed unfavorably by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100